Perspective Therapeutics Facing Execution Risks in Bamzireotide Navoxetan's Development, RBC Says

11:47 AM EDT, 10/26/2026 (MT Newswires) -- Perspective Therapeutics (CATX) continues to face execution risks related to bamzireotide navoxetan's competitive target market, future phase 3 trial conduct and manufacturing build-out, RBC Capital Markets said in a Monday note. While the company's updated data in gastroenteropancreatic neuroendocrine tumors indicated activity, "a clear efficacy win" remains to be seen, the investment firm said. Objective response rate or ORR increased with a higher dose, but the opportunity for deeper responses is limited, RBC noted. "Efficacy has come in somewhat below our expectations," RBC analysts said, estimating about 50% in ORR. Potential upside remains from pending follow-ups, the investment firm added. RBC downgraded Perspective Therapeutics to sector perform from outperform and lowered its price target to $4 from $14. Price: 1.29, Change: -0.33, Percent Change: -20.19